Nanomedicine and macroscale materials in immuno-oncology.

Published on Jan 2, 2019in Chemical Society Reviews54.564
路 DOI :10.1039/C8CS00473K
Qingxue Sun5
Estimated H-index: 5
(RWTH Aachen University),
Matthias Barz32
Estimated H-index: 32
(University of Mainz)
+ 5 AuthorsYang Shi24
Estimated H-index: 24
(RWTH Aachen University)
Sources
Abstract
Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.
馃摉 Papers frequently viewed together
References138
Newest
#1Lutz Nuhn (UGent: Ghent University)H-Index: 24
#2Stefaan De Koker (UGent: Ghent University)H-Index: 34
Last. Bruno G. De Geest (UGent: Ghent University)H-Index: 54
view all 14 authors...
Localized therapeutic modalities that subvert the tumor microenvironment from immune-suppressive to pro-immunogenic can elicit systemic antitumor immune responses that induce regression of directly treated as well as nontreated distal tumors. A key toward generating robust antitumor T cell responses is the activation of dendritic cells (DCs) in the tumor microenvironment. Treatment with agonists triggering various pattern recognition receptors is very efficient to activate DCs, yet suffers from ...
Source
#2Stephen Y. Chui (Genentech)H-Index: 15
#3Leisha A. Emens (University of Pittsburgh)H-Index: 54
Abstract Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor鈥搉egative and human epidermal growth factor receptor 2 [HER2]鈥搉egative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)鈥損aclitaxel may enhance the anticancer activity of atezolizumab. Methods In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitax...
Source
#1Nikolaos Mitrousis (U of T: University of Toronto)H-Index: 6
#2Ana Fokina (U of T: University of Toronto)H-Index: 9
Last. Molly S. ShoichetH-Index: 97
view all 3 authors...
Cell transplantation holds immense potential for reversing diseases that are currently incurable and for regenerating tissues. However, poor cell survival, cell aggregation and lack of cell integration into the host tissue constitute major challenges for the clinical translation of cell transplantation approaches. Biomaterials can influence cell behaviour in vitro and in vivo. The mechanical and biochemical properties of biomaterials can be tailored to affect cell survival, differentiation and m...
Source
#1Marco RuellaH-Index: 26
#2Jun Xu (UPenn: University of Pennsylvania)H-Index: 9
Last. J. Joseph Melenhorst (UPenn: University of Pennsylvania)H-Index: 14
view all 26 authors...
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19鈥 leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.
Source
#1Li TangH-Index: 27
#2Yiran Zheng (MIT: Massachusetts Institute of Technology)H-Index: 12
Last. Darrell J. IrvineH-Index: 88
view all 12 authors...
Cytokines released after T cell activation improve the efficacy of T cell therapies in mice.
Source
#1Yugang Guo (EPFL: 脡cole Polytechnique F茅d茅rale de Lausanne)H-Index: 8
#2Kewen Lei (EPFL: 脡cole Polytechnique F茅d茅rale de Lausanne)H-Index: 9
Last. Li Tang (EPFL: 脡cole Polytechnique F茅d茅rale de Lausanne)H-Index: 27
view all 3 authors...
Cancer neoantigens derived from random somatic mutations in tumor tissue represent an attractive type of targets for the cancer immunotherapies including cancer vaccine. Vaccination against the tumor-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. Neoantigen-based cancer vaccines have recently showed marked therapeutic potential in both preclinical and early-phase clinical studies. However, significant challenges rem...
Source
#1Christopher B. Rodell (Harvard University)H-Index: 22
#2Sean P. Arlauckas (Harvard University)H-Index: 12
Last. Ralph Weissleder (Harvard University)H-Index: 207
view all 9 authors...
Tumour-associated macrophages are abundant in many cancers, and often display an immune-suppressive M2-like phenotype that fosters tumour growth and promotes resistance to therapy. Yet, macrophages are highly plastic and can also acquire an anti-tumorigenic M1-like phenotype. Here, we show that R848, an agonist of the toll-like receptors TLR7 and TLR8 identified in a morphometric-based screen, is a potent driver of the M1 phenotype in vitro and that R848-loaded 尾-cyclodextrin nanoparticles (CDNP...
Source
#1Elisa Peranzoni (Paris V: Paris Descartes University)H-Index: 16
#2Jean Lemoine (Paris V: Paris Descartes University)H-Index: 1
Last. Emmanuel Donnadieu (Paris V: Paris Descartes University)H-Index: 23
view all 15 authors...
In a large proportion of cancer patients, CD8 T cells are excluded from the vicinity of cancer cells. The inability of CD8 T cells to reach tumor cells is considered an important mechanism of resistance to cancer immunotherapy. We show that, in human lung squamous-cell carcinomas, exclusion of CD8 T cells from tumor islets is correlated with a poor clinical outcome and with a low lymphocyte motility, as assessed by dynamic imaging on fresh tumor slices. In the tumor stroma, macrophages mediate l...
Source
#1Mikhail Binnewies (UCSF: University of California, San Francisco)H-Index: 14
#2Edward W. Roberts (UCSF: University of California, San Francisco)H-Index: 15
Last. Matthew F. Krummel (UCSF: University of California, San Francisco)H-Index: 67
view all 18 authors...
The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen pronounced clinical response with immunotherapeutic intervention; however, many more patients have experienced minimal or no clinical benefit when provided the same treatment. As technology has advanced, so has the understanding of the complexity and diversity of the immune context of the tumor microenvironment and its influence on response t...
Source
#1Roberta Zappasodi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 21
#2Taha Merghoub (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 71
Last. Jedd D. WolchokH-Index: 152
view all 3 authors...
Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune responses can regress tumors. However, this only occurs in a fraction of patients. Incorporating these therapies in more powerful combinations is thus a logical next step. Here, we review functional roles of immune checkpoints and molecular determinants of checkpoint-blockade clinical activity. Limited-size T聽cell-infiltrated tumors, differing substantially from "self," generally respond to checkpoint blockade. The...
Source
Cited By77
Newest
#1Mingming Wei (Northwest Normal University)
#2Honghong Rao (Lanzhou University)H-Index: 9
Last. Xiaoquan Lu (Northwest Normal University)H-Index: 51
view all 0 authors...
Abstract null null Photothermometric sensing strategies as a powerful point-of-care testing (POCT) method have attracted great interest in various chem/biosensing fields. Though considerable progresses have been made for a large number of colorimetric, fluorescent and electrochemical sensors in the fields of disease diagnosis, health management and environmental monitoring, most of these traditional methods often suffer from some obvious deficiencies like high background signals, uncontrollable ...
Source
#2Qiang Zhang (Soochow University (Suzhou))H-Index: 2
Bromodomain and extra-terminal (BET) proteins are attractive targets for treating various malignancies including melanoma. The inhibition of BET bromodomains, e.g. with JQ1, is found to downregulate the expression of both c-MYC oncoprotein and programmed cell death ligand 1 (PD-L1), which play a crucial role in tumor growth and the immunosuppressive tumor microenvironment, respectively. The BET bromodomain inhibitors like JQ1 though exhibiting high selectivity and affinity show usually low bioav...
Source
#1Yan Yang (Nanjing Medical University)H-Index: 3
#2Yang Yang (NU: Nanjing University)H-Index: 56
Last. Hanqing Qian (Nanjing Medical University)H-Index: 1
view all 7 authors...
Immunotherapy has emerged as one of the most promising treatments for cancer in recent years. However, it works only for a small proportion of patients, which can in part be attributed to the immunosuppressive tumor microenvironment (TME). Tumor associated macrophages (TAMs) are the critical components of tumors and play an important role in the development of the immunosuppressive TME. The transition of TAMs from the pro-tumor (M2) phenotype to anti-tumor (M1) phenotype is crucial for the immun...
Source
#1Sylwia Milewska (UMB: Medical University of Bia艂ystok)
#2Katarzyna Niemirowicz-Laskowska (UMB: Medical University of Bia艂ystok)H-Index: 7
Last. Halina Car (UMB: Medical University of Bia艂ystok)H-Index: 17
view all 6 authors...
Nanotherapy is a part of nanomedicine that involves nanoparticles as carriers to deliver drugs to target locations. This novel targeting approach has been found to resolve various problems, especially those associated with cancer treatment. In nanotherapy, the carrier plays a crucial role in handling many of the existing challenges, including drug protection before early-stage degradations of active substances, allowing them to reach targeted cells and overcome cell resistance mechanisms. The pr...
Source
#1Yang Shi (RWTH Aachen University)H-Index: 24
Abstract null null Current immuno-oncology primarily focuses on adaptive cellular immunity mediated by T lymphocytes. The other important lymphocytes, B cells, are largely ignored in cancer immunotherapy. B cells are generally considered to be responsible for humoral immune response to viral and bacterial infections. The role of B cells in cancer immunity has long been under debate. Recently, increasing evidence from both preclinical and clinical research has shown that B cells can also induce p...
Source
#1Manjunatha Reddy (RVCE: R.V. College of Engineering)H-Index: 1
#2Sumathra Manokaran (RVCE: R.V. College of Engineering)H-Index: 6
view all 3 authors...
The present standard therapies for cancer; surgery, anti-cancer drugs and radiotherapy, have major issues in advanced cancers especially, it is unlikely that they will cure the disease permanently. They require huge medical expenditure and the adverse side effects accompanying them put many patients in anguish. These problems may be considered as a result of initiating treatments without considering the root cause of cancer- "the change in energy metabolism". Tumor cells have unique metabolic ch...
#1Binbin Ding (CAS: Chinese Academy of Sciences)H-Index: 16
#2Jun Yue (SYSU: Sun Yat-sen University)H-Index: 15
Last. Jun Lin (USTC: University of Science and Technology of China)H-Index: 101
view all 5 authors...
Immunotherapy, a strategy that leverages the host immune function to fight against cancer, plays an increasingly important role in clinical tumor therapy. In spite of the great success achieved in not only clinic treatment but also basic research, cancer immunotherapy still faces many huge challenges. Manganese oxide nanomaterials (MONs), as ideal tumor microenvironment (TME)-responsive biomaterials, are able to dramatically elicit anti-tumor immune responses via multiple ways, indicating a grea...
Source
#1Serge Mignani (Paris V: Paris Descartes University)H-Index: 32
#2Xiangyang Shi (Donghua University)H-Index: 89
Last. Jean-Pierre Majoral (University of Toulouse)H-Index: 44
view all 6 authors...
Abstract null null Among the numerous nanomedicine formulations, dendrimers have emerged as original, efficient, carefully assembled, hyperbranched, polymeric nanoparticles based on synthetic monomers. Dendrimers are used either as nanocarriers of drugs or as drugs themselves. When used as drug carriers, dendrimers are considered 鈥榖est-in-class agents鈥, modifying and enhancing the pharmacokinetic and pharmacodynamic properties of the active entities encapsulated or conjugated with the dendrimers...
Source
#1Baranya Murugan (SASTRA: Shanmugha Arts, Science, Technology & Research Academy)H-Index: 4
#2Suresh Sagadevan (UM: University of Malaya)H-Index: 22
Last. Mohd Rafie Johan (UM: University of Malaya)H-Index: 30
view all 6 authors...
Source
#1Ramar Thangam (KU: Korea University)H-Index: 27
#2Kapil D. Patel (KU: Korea University)H-Index: 23
Last. Ramasamy Paulmurugan (Stanford University)H-Index: 46
view all 0 authors...
Engineering polymeric nanoparticles for their shape, size, surface chemistry, and functionalization using various targeting molecules has shown improved biomedical applications for nanoparticles. Polymeric nanoparticles have created tremendous therapeutic platforms, particularly applications related to chemo- and immunotherapies in cancer. Recently advancements in immunotherapies have broadened this field in immunology and biomedical engineering, where 鈥渋mmunoengineering鈥 creates solutions to ta...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.